A study featuring the participation of Fisabio (Foundation for the Promotion of Health and Biomedical Research of Valencia Region), dependent on the Conselleria de Sanitat Universal i Salut Pública, has found that the predominant lineage in Europe of gonococcus—the bacterium which causes gonorrhea—is resistant to one of the two drugs, among others, most commonly used today to treat this disease.
The bacterium Neisseria gonorrhoeae, commonly known as gonococcus, is the cause of gonorrhea, a sexually transmitted disease that is estimated to affect 82 million people worldwide each year. In this context, surveillance of its lineages is necessary to establish the most effective treatments with scientific evidence.
Leonor Sánchez-Busó, a researcher at Fisabio and Plan GenT of the Conselleria de Sanitat Universal i Salut Pública explains that "Compared to two previous surveillance programs, the results of this genomic surveillance study show the expansion of a lineage throughout Europe that is resistant to azithromycin, which compromises the most common treatment for these infections."
This study is an international collaboration resulting from a resistance surveillance program within the framework of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) organized by the European Center of Disease Prevention and Control and in which the Centre for Genomic Pathogen Surveillance (Oxford University, United Kingdom), the UK Health Protection Agency (London, United Kingdom) and the World Health Organization Collaborating Centre in örebro University Hospital (Sweden) also participated.
The methodology consisted of genomic sequencing and the analysis of 2,375 gonococcus isolates collected in 2018 in 26 countries of the European Economic Area. With this material, links between different genomic lineages, antimicrobial resistance and epidemiological information have been analyzed.
This lineage contains in its genome a mosaic in the mtrCDE efflux pump that causes resistance to azithromycin, and is significantly associated with pharyngeal infections in risk groups. Fortunately, this collection from 2018 does not show mutations that could compromise treatment of this infection with potential new antibiotics, such as zoliflodacin or gepotidacin."
Leonor Sánchez-Busó, lead author of the article
The study has been published in the prestigious scientific journal The Lancet Microbe and will be of great importance to study the introduction and dynamics of lineages with resistance to antibiotics in Europe as well as in the Valencian Community. One of the researcher's lines of work is this resistance in the Valencian Community, for which she collaborates with the hospitals of the Valencian public health network.
Specifically, thirteen hospitals in the Community have collaborated or will soon collaborate in supplying samples for gonococcus surveillance tasks. In the province of Valencia, the Hospital Universitario de la Ribera, the Hospital Universitario y Politécnico La Fe, the Hospital General Universitario in València, the Hospital Comarcal Francesc de Borja, the Hospital Clínico Universitario in Valencia, the Hospital Arnau de Vilanova, the Hospital Universitario Doctor Peset and the Hospital Lluís Alcanyís in Xàtiva and the Hospital de Manises.
In the rest of the territory, the Hospital Universitario Sant Joan in Alicante, the Hospital Universitario de La Plana, the Hospital General Universitario in Castellón and the Hospital Comarcal in Vinaròs contribute or will contribute to the research. In addition, work continues on the incorporation of new centers that allow better coverage of the entire territory of the Valencian Community.
STD prevention
In addition, the Ministry of Health carries out important work to prevent sexually transmitted diseases, such as gonorrhea.
In fact, the Valencian public health system has a network of Sexual and Reproductive Health Centers distributed among the various health departments made up of 80 care centers, located in the health centers and hospital facilities.
At the healthcare level, in 2021, these centers provided a total of 390,305 consultations. The work they carry out focuses on offering information and providing contraceptive methods, guidance and attention for sterility, control and treatment of sexually transmitted diseases, prenatal and genetic advice, voluntary interruption of pregnancy, or early detection of genital and breast pathologies, among others.
Funding programs
The project is funded by the Conselleria de Sanitat Universal i Salut Pública through grants from the Plan GenT (Program to support talented researchers) for hiring doctoral research staff with international experience to join research centers in the field of healthcare and centers of the National Health System in the Valencian Community: annex I file number no. CDEI-06/20-B.
In addition, it also has funding from the Ministry of Science, Innovation and Universities in its 2020 Call for GRANTS FOR "R&D&I PROJECTS", within the framework of Spanish programs for the generation of knowledge and scientific and technological strengthening of the R+D+I system oriented to the challenges of society, within the Spanish plan for scientific and technical innovation research 2017-2020, with file number PID2020-120113RA-I00/ AEI / 10.13039/501100011033.
Innovative bacteria-based therapy shows promise against cancer